GENB (Generate Biomedicines) EPS without NRI: $ (TTM As of Dec. 2025)


GENB Generate Biomedicines Inc GENB
6 GF Score
Price $16.92
! 2 Warning Signs
View Full Analysis

What is Generate Biomedicines EPS without NRI?

Generate Biomedicines GENB +2.18% 6 EPS without NRI is $ as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 1,172 Biotechnology companies, Generate Biomedicines ranks worse than 85324.15% on this metric.

Generate Biomedicines's earnings per share without non-recurring items for the six months ended in Dec. 2025 was $-2.18.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Generate Biomedicines's EPS without NRI or its related term are showing as below:

GENB's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.8
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Generate Biomedicines's EPS (Diluted) for the six months ended in Dec. 2025 was $-2.18.

Generate Biomedicines's EPS (Basic) for the six months ended in Dec. 2025 was $-2.18.


Generate Biomedicines  (NAS:GENB) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Generate Biomedicines EPS without NRI Related Terms


Generate Biomedicines EPS without NRI Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines EPS without NRI Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
EPS without NRI
-1.70 -2.18

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
EPS without NRI -1.70 -2.18

GENB vs PVLA, SLBT, NKTR: EPS without NRI Comparison

For the Biotechnology subindustry, Generate Biomedicines's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Generate Biomedicines PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generate Biomedicines's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Generate Biomedicines's PE Ratio without NRI falls into.


GENB
6GF Score
Generate Biomedicines Inc GENB
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generate Biomedicines EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $ mean?
Generate Biomedicines (GENB) has a EPS without NRI of $ as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Generate Biomedicines and its competitors. According to the industry distribution chart, Generate Biomedicines ranks #999999 out of 1172 companies in the Biotechnology industry.
Is Generate Biomedicines' EPS without NRI too high?
Generate Biomedicines' current EPS without NRI is $. Based on the distribution chart, Generate Biomedicines ranks #999999 out of 1172 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' EPS without NRI compare to PVLA and SLBT?
According to the Biotechnology industry distribution chart, Generate Biomedicines ranks #999999 out of 1172 companies for EPS without NRI. This places Generate Biomedicines in the lower half of its industry. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Generate Biomedicines and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Generate Biomedicines's current EPS without NRI is $. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current EPS without NRI of $. The current EPS without NRI is $. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current EPS without NRI is $ as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.92
Price